Besides ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy adequate to tolerate FCR therapy, should be great candidates with the latter, Using the gain staying that this therapy could be finished in six months when ibrutinib have to be taken indefinitely. This feature could be especially valuable for non-compliant patients or… Read More